Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

260
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
260
Rh Blood Group01:19

Rh Blood Group

1.2K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.2K
Hematopoiesis01:21

Hematopoiesis

4.9K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
4.9K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

3.6K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
3.6K
Teratogenicity01:07

Teratogenicity

2.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

1.2K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Readmission and Late Mortality Among Children With Congenital Diaphragmatic Hernia.

JAMA network open·2026
Same author

High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study.

Journal of autoimmunity·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Focus on the bleeding risk of elderly patients with myelodysplastic syndromes.

Journal of thrombosis and haemostasis : JTH·2026
Same author

High frequency of CD95<sup>+</sup>/CD45RA<sup>-</sup> regulatory T cells defines an immunosuppressive profile associated with MDS progression.

British journal of haematology·2026
Same author

Management of preterm pre-labor rupture of membranes between 24 and 34 weeks: A before-and-after study of the implementation and modifications of an outpatient management protocol.

Acta obstetricia et gynecologica Scandinavica·2026

Related Experiment Video

Updated: May 10, 2025

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

1.9K

[Haematological malignancies in pregnancy].

Justine Decroocq1, Sangsong Wu1, Mathilde Barrois2

  • 1Service d'hématologie clinique, Hôpital Cochin-Port Royal (AP-HP), Institut Cochin, Université Paris Cité, Paris, France.

Medecine Sciences : M/S
|April 28, 2025
PubMed
Summary
This summary is machine-generated.

Managing hematological malignancies during pregnancy is complex, requiring multidisciplinary care for maternal and fetal risks. More research is crucial to optimize treatment and patient access to clinical trials.

More Related Videos

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

27.9K
Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

380

Related Experiment Videos

Last Updated: May 10, 2025

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

1.9K
Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

27.9K
Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

380

Area of Science:

  • Hematology
  • Obstetrics
  • Oncology

Background:

  • Hematological malignancies in pregnancy are rare and pose significant challenges.
  • Management requires balancing maternal physiological changes with fetal risks from treatment.
  • Limited data currently exists to guide optimal patient care strategies.

Purpose of the Study:

  • To provide an overview of the complexities in managing hematological malignancies during pregnancy.
  • To highlight diagnostic, therapeutic, and prognostic challenges.
  • To emphasize the need for comprehensive research and patient involvement in clinical trials.

Main Methods:

  • Literature review and synthesis of existing knowledge on hematological malignancies in pregnancy.
  • Analysis of diagnostic, therapeutic, and prognostic considerations.
  • Discussion of multidisciplinary collaboration requirements.

Main Results:

  • Pregnancy complicates hematological malignancy management due to maternal and fetal risks.
  • Treatment decisions involve careful consideration of potential adverse effects on both mother and fetus.
  • Limited research hinders evidence-based care optimization.

Conclusions:

  • Effective management necessitates a multidisciplinary approach involving hematologists, oncologists, and obstetricians.
  • Further research is essential to improve understanding, treatment impact assessment, and care optimization.
  • Involving pregnant patients in clinical trials is key to improving access to novel therapies.